Who are Radium-223's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [Ga-68]PSMA, Sr-89, Ga-68-DOTATOC, Technetium Tc99m Sestamibi, Tc 99m filtered sulfur colloid, [F-18]-Fludeoxyglucose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/radium-223.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Radium-223 — Competitive Intelligence Brief

Radium-223 (radium-223) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

marketed Radiopharmaceutical Bone cells Oncology Live · refreshed every 30 min

Target snapshot

Radium-223 (radium-223) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Radium-223 TARGET	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism
Ga-68-DOTATOC	Ga-68-DOTATOC	Weill Medical College of Cornell University	marketed	Radiopharmaceutical	Somatostatin receptors (SSTRs) on neuroendocrine tumor cells
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent
[F-18]-Fludeoxyglucose	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

Amsterdam UMC, location VUmc · 1 drug in this class
Blue Earth Diagnostics · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
ITEL Telecomunicazioni Srl · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radium-223 — Competitive Intelligence Brief. https://druglandscape.com/ci/radium-223. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab